TY - JOUR
TI - Anti–SARS-CoV-2 antibody responses in convalescent plasma donors are increased in hospitalized patients; subanalyses of a phase 2 clinical study
AU - Terpos, E.
AU - Politou, M.
AU - Sergentanis, T.N.
AU - Mentis, A.
AU - Rosati, M.
AU - Stellas, D.
AU - Bear, J.
AU - Hu, X.
AU - Felber, B.K.
AU - Pappa, V.
AU - Pagoni, M.
AU - Grouzi, E.
AU - Labropoulou, S.
AU - Charitaki, I.
AU - Ntanasis-Stathopoulos, I.
AU - Moschandreou, D.
AU - Bouhla, A.
AU - Saridakis, S.
AU - Korompoki, E.
AU - Giatra, C.
AU - Bagratuni, T.
AU - Pefanis, A.
AU - Papageorgiou, S.
AU - Spyridonidis, A.
AU - Antoniadou, A.
AU - Kotanidou, A.
AU - Syrigos, K.
AU - Stamoulis, K.
AU - Panayiotakopoulos, G.
AU - Tsiodras, S.
AU - Alexopoulos, L.
AU - Dimopoulos, M.A.
AU - Pavlakis, G.N.
JO - Microorganisms
PY - 2020
VL - 8
TODO - 12
SP - 1-19
PB - MDPI AG
SN - null
TODO - 10.3390/microorganisms8121885
TODO - null
TODO - We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14–104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
ER -